PARP7作为激活癌症抗瘤免疫力的新目标
Katerina Popova1,2,3, Johannes Benedum1,2,4,5,6, Magdalena Engl1,2,4,5,6
1Department of Radiation Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
EMBO molecular medicine
|March 25, 2025
概括
多 (ADP-ribose) 聚合酶7 (PARP7) 是一种单-ADP-ribosyl转移酶,调节关键信号通路和蛋白质稳定性. 这篇评论探讨了PARP7的研究.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- ADP-ribosyl转移酶 (ARTs) 催化了ADP-ribose添加 (PARylation/MARylation) 的过程.
- PARP7,一种单一ART,对I型干扰素 (IFN-I) 和核受体信号进行负调节.
- 异常的PARP7表达与癌症进展和免疫逃避有关.
研究的目的:
- 审查PARP7.7的酶性质和生物功能.
- 讨论已知的PARP7基质及其差异调节.
- 探索PARP7在癌症中的作用和潜在的治疗向.
主要方法:
- 关于PARP7酶活性的文献综述.
- 分析PARP7介导的基质修饰和稳定性.
- 检查PARP7在癌症信号通路中的作用.
主要成果:
- PARP7不同影响蛋白质稳定性:保护FRA1,但针对AHR和ER进行降解.
- PARP7通过DTX3L-PARP9.9.影响雄激素受体 (AR) 活性.
- PARP7的异常表达有助于癌症的进展和免疫逃避.
结论:
- PARP7是细胞信号传递的关键调节者,具有多种基质相互作用.
- 了解PARP7在癌症中的作用提供了潜在的治疗策略.
- 准PARP7可能为癌症治疗提供新的途径.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Tumor Immunotherapy
450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K


